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n our modern era of medical science character-
zed by microsatellite arrays and gene therapy, it
ecomes increasingly challenging to advance the
nvestigative needs of what I call ‘‘high impact
rphan diseases.’’ These conditions occur com-
only, present remarkably high morbidity and
ortality, yet receive little if any research fund-
ng. Perhaps their common occurrence generates
sense of tolerance to their public health impact
nd encourages resources to ﬂow toward less
‘garden-variety’’ conditions that promise cutting
dge diagnostics and therapies.
Until recently, chronic obstructive pulmonary
isease (COPD) as the fourth leading cause of
eath worldwide represented one such high impact
rphan disease. Now that the National Institutes of
ealth has initiated a major public awareness cam-
aign to address the epidemic of COPD [1], it may
opefully lose its orphan status.
The future, however, does not look so promis-
ng for thoracic empyema. Pleural space infections
omplicating pneumonia remain common and carry
tremendous global health burden in terms of
oth morbidity and mortality [2,3]. Patient series
eport mortality rates between 7 and 33% for
ospitalized patients [3—5] with death occurring
n more than 50% of the elderly and those with
omorbidites [3,5]. Moreover, epidemiologic stud-
es recently established that empyema is on the
ise. In the state of Washington in the United States,
he incidence rate of empyema has increased by
.8% each year from 1987 to 2004 [6]. Canadian data
eport an aggregate 12.4% age-adjusted increase in
mpyema incidence from 1995 to 2003 [7]. Future
emographics of an increasing population of older
atients, longer survival of patients with comorbidi-
ies, and emerging respiratory pathogens with poor
t
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rug susceptibility patterns will most likely main-
ain these worrisome trends.
So empyema is indeed a high impact condition
rom a public health perspective, but what makes
t an orphan disease? In my opinion, inadequate
esearch funding has limited our knowledge of the
isease and retarded the development of evidence-
ased diagnostic and therapeutic algorithms.
Consider the diagnosis of empyema. All existing
eports indicate that pleural infections among hos-
italized patients admitted with pneumonia remain
nder diagnosed partly because clinicians under
ppreciate the importance of early diagnosis and
rompt drainage [8—10]. Moreover, no comparative
tudies with outcome data guide the application
f modern chest imaging for selecting patients to
eceive individualized therapy. The standard chest
adiograph is woefully insensitive for detecting
leural ﬂuid (200—500ml pleural ﬂuid required),
et it remains the most commonly performed
creening study for parapneumonic effusions. Ultra-
onography (US) represents a major advance in
maging the pleural space with an ability to detect
s little as 5ml of pleural ﬂuid. Most patients
t risk for parapneumonic effusions, however, do
ot get screened with US. Also, although various
atterns of US images may have diagnostic impli-
ations for pleural space infections [11,12], none
as been sufﬁciently investigated to obviate thora-
entesis for patients with parapneumonic effusions.
he literature on chest computerized tomography
CT) for pleural infections is similarly characterized
y observational and descriptive studies without
he robust prospective comparative studies pub-
ished for other cardiopulmonary conditions, such
s pulmonary embolism. Pleural ﬂuid analysis for
stablishing the need for drainage remains similarly
Sciences. Published by Elsevier Ltd. All rights reserved.
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ill deﬁned. Professional society guidelines recom-
mend the staging of pleural infections with pleural
ﬂuid chemic tests, such as lactate dehydrogenase
(LDH) and pH, to aid drainage decisions. The data
for pH, however, derive from ﬂawed observational
studies, and no outcome data support the proposed
cut off points for LDH [13]. The role of procalcitonin
in diagnosing pleural infection remains unexamined
despite an explosion of research of this biomarker
for other infectious conditions.
Research data regarding the therapy of empyema
remains almost entirely lacking. No outcome
studies guide empiric antibiotic therapy, which per-
petuates the adage to direct therapy toward the
underlying pneumonia pending pleural ﬂuid culture
results. Traditional approaches of blind insertion
of a large-bore chest tube by surgical intercostal
incisional techniques [14,15] are slowly giving way
in some centers to image-guided small-bore pig-
tail catheter insertion [16,17], but no comparative
studies exist and experts still differ regarding
the desirability of large-bore [15,18] versus small-
bore chest tubes and whether real-time imaging
is required [19,20]. Once a catheter is placed for
drainage, the duration of drainage before con-
version to more aggressive interventions remains
debatable with experts recommending from 2 to
7 days [4,21—24] to as long as many weeks [25].
The role of ﬁbrinolytic therapy for loculated effu-
sions is unknown. The Multicenter Intrapleural
Sepsis Trial (MIST1) trial [26] represents the only
large prospective randomized study of ﬁbrinolysis,
but the study’s methodology limits generalizability
[27]. The study included nonstandardized treat-
ment algorithms without the use of advanced
chest imaging. The MIST1 selection of streptokinase
for ﬁbrinolysis does not inform present questions
regarding the effectiveness of intrapleural recom-
binant tissue plasminogen activator, which is now
more commonly used for empyema drainage [20].
Perhaps most troubling is the absence of ade-
quate studies regarding the role of thoracoscopy
or thoracotomy for draining pleural infections.
Although many physicians use US or CT imag-
ing to determine the need for primary surgical
drainage and the speciﬁc surgical technique, recent
studies indicate a poor association of imaging
results with patient outcomes with therapy [16,28].
Patient selection for and timing of surgical drainage
remains a matter of expert opinion and varies
widely between institutions.So what can physicians do in managing this com-
mon and important condition for which adequate
research remains lacking? I believe we need to
ﬁrst accept our uncertainty and avoid over conﬁ-
dence in our — and our colleagues’ — ability to
C
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ecommend ideal therapy. An adequate evidence
ase simply does not exist to warrant too much
onﬁdence or arbitrary opinions; existing practice
ariation between institutions proves that consen-
us does not exist. Consequently, patients beneﬁt
rom a team-based approach wherein pulmonary
hysicians, interventional radiologists, and thoracic
urgeons convene with each new patient to review
ll available clinical information and construct a
ollaborative approach akin to a tumor board. This
pproach has proven valuable for guiding diagnostic
nd therapeutic decisions for patients with idio-
athic pulmonary ﬁbrosis [29].
All experts agree with some fundamental princi-
les of managing empyemas. Hospitalized patients
ith pneumonia should undergo evaluation to
xclude clinically important volumes of pleural
uid. They also agree that parapneumonic effusions
f sufﬁcient size should be sampled by thora-
entesis. But once evaluated by thoracentesis, a
oordinated approach is necessary to determine
lgorithms of care. In order to validate the algo-
ithms institutions might adopt, clinical outcomes
hould be closely monitored. Case series in the
iterature establish achievable outcomes in terms
f duration of hospitalization and survival that
hould be achieved. If not achieved, local algo-
ithms should be modiﬁed and reevaluated.
But for the future, continued status of empyema
s a high-impact orphan disease strikes me as
nacceptable. Our patients with pleural infections
epend on us to have knowledge from robust and
ell-designed studies to guide their diagnosis and
herapy. Learning from the success of advocates for
OPD, we should encourage our funding agencies
o recognize the public health impact of empyema
nd fund adequate research. It is time for empyema
o relinquish its title as an orphan and regain its
ell-deserved status from the preantibiotic era
s a harbinger of death. As busy clinicians, we
eed to advocate for more empyema research.
ir William Osler, who himself died of empyema,
eminds us, ‘‘At whose door so often lies the
esponsibility for death in cases of empyema but at
hat of the busy doctor . . .’’ [30]. He was speak-
ng of busy physicians who fail to recognize the
arly signs of pleural infection and thereby delay
herapy. We might now interpret his comments as
n admonishment to encourage a more complete
nderstanding of mechanisms of disease and man-
gement approaches.onﬂict of interest statement
unding: No funding sources.
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